Testing anakinra to reduce inflammation in pediatric sepsis MODS
Treatments studied
Part of Infections clinical trials.
This study tests whether a medicine called anakinra can “turn down” harmful inflammation in children with severe illness from sepsis. It aims to improve organ function when multiple organs are starting to fail.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 18 years old (and not born too early; at least 40 weeks corrected age)
- You are currently in the PICU or CICU (intensive care for very sick patients)
- In the last 3 days, at least two new organ problems have appeared after the sepsis started
- There is a known or suspected infection that triggered the sepsis
- Your weight is 3 kg or more
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medicine called anakinra can help children with acute myocarditis (heart inflammation) in the ICU. It aims to see if the drug reduces heart damage and improves recovery.
This trial is testing several different treatments to find the best one for each person with sepsis. It looks at specific 'treatable traits' like inflammation, blood clotting problems, or immune system issues to match you with the right therapy. The goal is to improve recovery and survival.
This study tests how three different anti-inflammatory drugs (dexamethasone, tocilizumab, and anakinra) affect the body's immune response during a controlled, short-term inflammation. It is for healthy young men who can safely receive an experimental substance that temporarily mimics an infection.
This trial tests whether anakinra is at least as effective as standard treatment for children with Kawasaki disease. It aims to prevent heart complications caused by inflammation in the blood vessels.
This study compares two treatments—anakinra and IVIG—for children with Kawasaki disease who still have fever after their first standard IVIG treatment. It aims to find which option works better and is safer for “IVIG non-responders” who may be at risk for heart complications.
This study tests whether a medication called anakinra can help treat asthma attacks in people who already take daily asthma controller medications. Anakinra works by reducing inflammation in the airways, and researchers want to see if it can help people recover faster from moderate asthma flare-ups.
Hear when a new Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.